Israel's Medtech Market Evolution: Seeking The Next Big Thing
Medtronic’s multi-billion-dollar acquisition of Mazor Robotics in 2018 marked a record-breaking milestone for Israel’s life sciences industry as the largest amount ever paid for an Israeli company in the medical sector, beating Mitsubishi Tanabe Pharma’s $1.1 billion acquisition of Neuroderm in 2017. In Vivo investigates how aMoon II, a new VC fund, aims to produce the industry’s next big giant.
You may also be interested in...
Medtronic is straightening up as a market leader in spinal surgery after agreeing to buy the shares of Mazor Robotics that it does not already own. The $1.3bn deal builds on an existing agreement between the companies formed in May 2016 and strengthens Medtronic as the front runner in the spine robotics field.
Israel's appetite for biopharma investment is growing, but competition for cash is still tough and local investors are not only looking at regional startups to place their bets on.
Seed investor Novalis Biotechnology Incubator sees Enzyre’s technology as an opportunity to get testing closer to patients.